基于外周血IL-6/STAT3信号通路探讨消癌平联合FOLFOX6方案治疗晚期直肠癌的疗效及其作用机制

doi:10.3969/j.issn.1001-8131.2025.03.003

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (572 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To investigate the efficacy and mechanism of Xiaoaiping combined with FOLFOX6 regimen in the treatment of advanced rectal cancer based on peripheral blood interleukin-6(IL-6)/signal transduction factor and transcriptional activation factor(STAT3)signaling pathway. Methods 102 patients with advanced rectal cancer were divided into control group and experimental group by random number table method,with 51 cases in each group.The control group received FOLFOX6 chemotherapy,and the experimental group received Xiaocarpine on the basis of the control group.Clinical efficacy,conventional tumor markers [carcinoembryonic antigen(CEA),glycoprotein antigen 199(CA199)],cellular immune function,and peripheral blood IL-6/STAT3 signaling pathway related indexes[IL-6,STAT3] were observed and compared between the two groups. Results The Objective response rate(ORR)and disease control rate(DCR)of the experimental group were higher than those of the control group(P<0.05).After treatment,CEA and CA199 in experimental group were lower than those in control group(P<0.05).After treatment,CD8⁺ in the experimental group was lower than that in the control group,and CD3⁺,CD4⁺,CD4⁺/ CD8⁺ were higher than that in the control group(P<0.05).IL-6 and STAT3 in the experimental group were lower than those in the control group after treatment(P<0.05). Conclusion Xiaoaiping combined with FOLFOX6 regimen in the treatment of advanced rectal cancer is helpful to improve clinical efficacy and reduce the level of serum tumor markers,which may be related to the regulation of immunity and IL-6STAT3 signaling pathway in peripheral blood.

Key words： Interleukin-6 / signal transduction factor and transcription activation factor signaling pathway Xiaoaiping FOLFOX6 regimen Advanced rectal cancer Curative effect

Received: 26 February 2025

PACS:

R735.3+7

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Li Jing
	Hu Yuyue
	Ma Huili

Cite this article:

Li Jing,Hu Yuyue,Ma Huili. Investigate the Efficacy and Mechanism of Xiaoaiping Combined with FOLFOX6 Regimen in the Treatment of Advanced Rectal Cancer Based on IL-6/STAT3 Signaling Pathway in Peripheral Blood[J]. journal1, 2025, 45(3): 11-14.

URL:

http://www.hrbyybjb.org.cn/EN/10.3969/j.issn.1001-8131.2025.03.003 OR http://www.hrbyybjb.org.cn/EN/Y2025/V45/I3/11

[1] Body A,Prenen H,Lam M,et al.Neoadjuvant Therapy for Locally Advanced Rectal Cancer: Recent Advances and Ongoing Challenges[J].Clin Colorectal Cancer,2021,20(1):29-41.
[2] Song SH,Park JS,Kang MK,et al.Initial experience of preoperative short-course radiotherapy followed by oxaliplatin-based consolidation chemotherapy for locally advanced rectal cancer[J].Int J Colorectal Dis,2021,36(6):1279-1286.
[3] 王登灿,陈焰烽,郑炜,等.加味八珍汤联合mFOLFOX6方案对晚期结直肠癌患者肿瘤标志物、免疫功能和外周血PI3K-Akt信号通路的影响[J].现代生物医学进展,2023,23(4):666-670,713.
[4] 匡子禹,刘可心,李杰.消癌平注射液联合一线化疗治疗晚期胃癌疗效的系统评价及Meta分析[J].天津中医药,2024,41(7):857-864.
[5] 宋学梅,管玲.晚期直肠癌的免疫治疗结合新辅助放化疗临床研究进展[J].生命科学仪器,2023,21(z2):104.
[6] 中华人民共和国国家卫生和计划生育委员会医政医管局,中华医学会肿瘤学分会.结直肠癌诊疗规范(2015年版)[J].中国实用外科杂志,2015,35(11):1177-1191.
[7] 杨学宁,吴一龙.实体瘤治疗疗效评价标准-RECIST[J].循证医学,2004,4(2):85-90,111.
[8] 陈欣德,周帅,张茂容,等.消癌平注射液促进肺腺癌细胞凋亡的分子机制研究[J].皖南医学院学报,2022,41(3):209-213.
[9] 沙晓锋,张姣.安替可胶囊联合FOLFOX6方案对晚期胃癌患者血管生长因子、肿瘤标志物、生活质量的影响[J].现代中西医结合杂志,2020,29(15):1672-1675.
[10] 唐义东. 中药注射剂联合化疗治疗结直肠癌的网状Meta分析[D].沈阳:辽宁中医药大学,2019.
[11] 王祁民,孙利民,许剑峰.通关藤及其制剂消癌平抗肿瘤的相关性研究[J].临床误诊误治,2017,30(12):102-105.
[12] Jones AN,Scheurlen KM,Macleod A,et al.Obesity and Inflammatory Factors in the Progression of Early-Onset Colorectal Cancer[J].Cancers(Basel),2024,16(7):1403.
[13] 李双凤,黄家彦,韩笑,等.通关藤抗肿瘤主要成分及作用机制研究进展[J].药物评价研究,2023,46(1):187-197.